FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137605317> ?p ?o ?g. }

• W2137605317 endingPage "4729" @default.
• W2137605317 startingPage "4722" @default.
• W2137605317 abstract "Purpose Immunologic targeting of tumor-specific gene mutations may allow precise eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal tissues but widely expressed in glioblastoma multiforme (GBM) and other neoplasms. Patients and Methods A phase II, multicenter trial was undertaken to assess the immunogenicity of an EGFRvIII-targeted peptide vaccine and to estimate the progression-free survival (PFS) and overall survival (OS) of vaccinated patients with newly diagnosed EGFRvIII-expressing GBM with minimal residual disease. Intradermal vaccinations were given until toxicity or tumor progression was observed. Sample size was calculated to differentiate between PFS rates of 20% and 40% 6 months after vaccination. Results There were no symptomatic autoimmune reactions. The 6-month PFS rate after vaccination was 67% (95% CI, 40% to 83%) and after diagnosis was 94% (95% CI, 67% to 99%; n = 18). The median OS was 26.0 months (95% CI, 21.0 to 47.7 months). After adjustment for age and Karnofsky performance status, the OS of vaccinated patients was greater than that observed in a control group matched for eligibility criteria, prognostic factors, and temozolomide treatment (hazard ratio, 5.3; P = .0013; n = 17). The development of specific antibody (P = .025) or delayed-type hypersensitivity (P = .03) responses to EGFRvIII had a significant effect on OS. At recurrence, 82% (95% CI, 48% to 97%) of patients had lost EGFRvIII expression (P < .001). Conclusion EGFRvIII-targeted vaccination in patients with GBM warrants investigation in a phase III, randomized trial." @default.
• W2137605317 created "2016-06-24" @default.
• W2137605317 creator A5011590188 @default.
• W2137605317 creator A5014505996 @default.
• W2137605317 creator A5037596103 @default.
• W2137605317 creator A5041466780 @default.
• W2137605317 creator A5044465742 @default.
• W2137605317 creator A5057371623 @default.
• W2137605317 creator A5059965175 @default.
• W2137605317 creator A5063290790 @default.
• W2137605317 creator A5064627876 @default.
• W2137605317 creator A5070419159 @default.
• W2137605317 creator A5072142601 @default.
• W2137605317 creator A5073862375 @default.
• W2137605317 creator A5079081497 @default.
• W2137605317 creator A5083472710 @default.
• W2137605317 creator A5087959258 @default.
• W2137605317 creator A5091806633 @default.
• W2137605317 date "2010-11-01" @default.
• W2137605317 modified "2023-10-15" @default.
• W2137605317 title "Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma" @default.
• W2137605317 cites W1636699277 @default.
• W2137605317 cites W1959628099 @default.
• W2137605317 cites W1970174108 @default.
• W2137605317 cites W1974546646 @default.
• W2137605317 cites W1998293167 @default.
• W2137605317 cites W2010956784 @default.
• W2137605317 cites W2024441247 @default.
• W2137605317 cites W2043732412 @default.
• W2137605317 cites W2069743461 @default.
• W2137605317 cites W2075180002 @default.
• W2137605317 cites W2096287682 @default.
• W2137605317 cites W2098263349 @default.
• W2137605317 cites W2100567246 @default.
• W2137605317 cites W2105100844 @default.
• W2137605317 cites W2107520546 @default.
• W2137605317 cites W2117735567 @default.
• W2137605317 cites W2121625674 @default.
• W2137605317 cites W2121889629 @default.
• W2137605317 cites W2137046569 @default.
• W2137605317 cites W2140407529 @default.
• W2137605317 cites W2144616410 @default.
• W2137605317 cites W2155367074 @default.
• W2137605317 cites W2162630386 @default.
• W2137605317 cites W2232770029 @default.
• W2137605317 doi "https://doi.org/10.1200/jco.2010.28.6963" @default.
• W2137605317 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3020702" @default.
• W2137605317 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20921459" @default.
• W2137605317 hasPublicationYear "2010" @default.
• W2137605317 type Work @default.
• W2137605317 sameAs 2137605317 @default.
• W2137605317 citedByCount "689" @default.
• W2137605317 countsByYear W21376053172012 @default.
• W2137605317 countsByYear W21376053172013 @default.
• W2137605317 countsByYear W21376053172014 @default.
• W2137605317 countsByYear W21376053172015 @default.
• W2137605317 countsByYear W21376053172016 @default.
• W2137605317 countsByYear W21376053172017 @default.
• W2137605317 countsByYear W21376053172018 @default.
• W2137605317 countsByYear W21376053172019 @default.
• W2137605317 countsByYear W21376053172020 @default.
• W2137605317 countsByYear W21376053172021 @default.
• W2137605317 countsByYear W21376053172022 @default.
• W2137605317 countsByYear W21376053172023 @default.
• W2137605317 crossrefType "journal-article" @default.
• W2137605317 hasAuthorship W2137605317A5011590188 @default.
• W2137605317 hasAuthorship W2137605317A5014505996 @default.
• W2137605317 hasAuthorship W2137605317A5037596103 @default.
• W2137605317 hasAuthorship W2137605317A5041466780 @default.
• W2137605317 hasAuthorship W2137605317A5044465742 @default.
• W2137605317 hasAuthorship W2137605317A5057371623 @default.
• W2137605317 hasAuthorship W2137605317A5059965175 @default.
• W2137605317 hasAuthorship W2137605317A5063290790 @default.
• W2137605317 hasAuthorship W2137605317A5064627876 @default.
• W2137605317 hasAuthorship W2137605317A5070419159 @default.
• W2137605317 hasAuthorship W2137605317A5072142601 @default.
• W2137605317 hasAuthorship W2137605317A5073862375 @default.
• W2137605317 hasAuthorship W2137605317A5079081497 @default.
• W2137605317 hasAuthorship W2137605317A5083472710 @default.
• W2137605317 hasAuthorship W2137605317A5087959258 @default.
• W2137605317 hasAuthorship W2137605317A5091806633 @default.
• W2137605317 hasBestOaLocation W21376053171 @default.
• W2137605317 hasConcept C121608353 @default.
• W2137605317 hasConcept C126322002 @default.
• W2137605317 hasConcept C143998085 @default.
• W2137605317 hasConcept C203014093 @default.
• W2137605317 hasConcept C207103383 @default.
• W2137605317 hasConcept C22070199 @default.
• W2137605317 hasConcept C2776694085 @default.
• W2137605317 hasConcept C2777389519 @default.
• W2137605317 hasConcept C2777701055 @default.
• W2137605317 hasConcept C2779438470 @default.
• W2137605317 hasConcept C2780739268 @default.
• W2137605317 hasConcept C2780868878 @default.
• W2137605317 hasConcept C29730261 @default.
• W2137605317 hasConcept C44249647 @default.
• W2137605317 hasConcept C71924100 @default.
• W2137605317 hasConcept C8891405 @default.

• next